Boston Common Asset Management LLC Reduces Position in Roche Holding AG $RHHBY

Boston Common Asset Management LLC reduced its stake in Roche Holding AG (OTCMKTS:RHHBY) by 7.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 339,393 shares of the company’s stock after selling 29,160 shares during the quarter. Boston Common Asset Management LLC’s holdings in Roche were worth $17,575,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in RHHBY. Sentinel Trust Co. LBA purchased a new stake in Roche during the 3rd quarter worth about $878,000. Vestmark Advisory Solutions Inc. purchased a new position in Roche in the 3rd quarter valued at about $597,000. Altrius Capital Management Inc boosted its stake in shares of Roche by 4.0% during the 3rd quarter. Altrius Capital Management Inc now owns 198,278 shares of the company’s stock worth $8,290,000 after purchasing an additional 7,659 shares during the last quarter. Knuff & Co LLC purchased a new stake in shares of Roche during the second quarter worth about $255,000. Finally, Enterprise Financial Services Corp purchased a new stake in shares of Roche during the fourth quarter worth about $270,000.

Roche Stock Performance

OTCMKTS RHHBY opened at $48.84 on Tuesday. Roche Holding AG has a 12 month low of $34.75 and a 12 month high of $60.85. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. The company has a 50-day moving average of $55.10 and a 200-day moving average of $49.67.

Wall Street Analysts Forecast Growth

RHHBY has been the topic of several recent analyst reports. TD Cowen reissued a “hold” rating on shares of Roche in a research note on Tuesday, February 10th. JPMorgan Chase & Co. raised shares of Roche from an “underweight” rating to a “neutral” rating in a research note on Monday, December 8th. HSBC reiterated a “buy” rating and issued a $57.00 price target on shares of Roche in a report on Wednesday, December 10th. The Goldman Sachs Group raised Roche from a “sell” rating to a “hold” rating in a research note on Thursday, January 15th. Finally, Wolfe Research reaffirmed an “outperform” rating on shares of Roche in a research report on Thursday, February 26th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Roche presently has a consensus rating of “Hold” and an average price target of $57.00.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.